Cell & Gene Therapy Update with Joe DePinto, InspiroGene by McKesson | TWIRx
- 36m
- Transcript
Summary
Written by a model from the transcript; not yet reviewed.
This episode of the Pharmacy Podcast Network covers industry developments, including potential temporary FDA pathways for compounded peptides, a GAO investigation into Medicare Part D plans, and a new immunotherapy-based regimen for stage three colon cancer. In the main interview, Joe DePinto from InspiroGene by McKesson discusses the findings of the 2026 Cell and Gene Therapy Report. DePinto and the host explore how cell and gene therapies are expanding from top-tier academic centers into community hospitals and outpatient clinics, moving into therapeutic areas like autoimmune diseases and retinal disorders, and creating new treatment avenues for pediatric patients with sickle cell disease.
The discussion highlights how policy shifts at the FDA are helping reduce commercial barriers and clinical trial redundancies, paving the way for broader integration between specialty pharmacies and hub systems. The episode also features professional development tips from Jesse McCullough on maintaining a collector mindset for career accomplishments, plus previews of upcoming industry gatherings such as the Next Dose Summit.
- Maintain a regular log of your professional accomplishments in a notes app or word document so you are prepared when asked for an updated CV. 3:10
- Cell and gene therapy clinical trials are expanding into new therapeutic areas such as autoimmune diseases and retinal disorders. 18:25
- Cell and gene therapy treatment centers are expanding from academic institutions into community-based hospitals and outpatient clinics to treat patients closer to home. 24:51
- Ex vivo gene therapies are providing new treatment options for pediatric patients as young as two years old with sickle cell disease. 26:17
Chapters
- 0:05Podcast Introduction and Host Greeting
Hosts introduce the Pharmacy Podcast Network and welcome listeners to the episode.
- 0:5031-Day Challenge Introduction
Jesse McCullough explains the 31‑day challenge and shares a personal story about keeping a CV updated.
- 3:03Setting Reminders for Career Accolades
Jesse outlines how to set reminders to record accomplishments for future opportunities.
- 8:51Twerks News Segment Begins
Hosts transition to the news segment, introducing Vox in the Box for FDA updates.
- 11:39GAO Report on PBM Reform Debate
Analysis of the GAO report’s findings on Medicare Part D plans and its impact on independent pharmacies.
- 13:53FDA Approves Immunotherapy for Colon Cancer
Announcement of the FDA’s approval of a new immunotherapy regimen for stage three colon cancer.
- 15:13Cell & Gene Therapy Update with Joe DePinto
Joe DePinto discusses the 2026 Cell & Gene Therapy Report, trends, and future outlook.
Highlights
- 1:45
Keeping a Career Accomplishments Logstrategy
Jesse McCullough explains how difficult it is to update a CV after long periods and challenges listeners to set phone reminders to regularly record their professional accomplishments.
- 9:05
FDA Consideration for Compounded Peptidesdata
A news update reveals that the Trump administration is considering a temporary pathway for compounded peptides while the FDA works on permanent regulations, raising questions about patient safety and clinical evidence.
- 11:29
GAO Investigation on Medicare Part Ddata
The discussion covers a GAO report on vertically integrated Medicare Part D plans, noting that affiliated pharmacies account for substantial drug utilization while reigniting debate over independent pharmacy reimbursement rates.
- 18:07
Expanding Cell and Gene Therapy Reportinsight
Joe DePinto discusses the third annual InspiroGene report, highlighting an expansion of research into autoimmune diseases and ophthalmology alongside traditional oncology and hematology pipelines.
- 22:51
FDA Policy Changes and Approvalsinsight
DePinto outlines positive shifts at the FDA, including policies that have eliminated certain REMS follow-up duration requirements and helped streamline late-stage products toward commercialization.
- 25:03
Shift to Outpatient Community Settingsinsight
The guest explains how cell and gene therapies are increasingly delivered in outpatient and community settings, allowing patients to receive treatments safely and efficiently closer to home.
- 26:17
Pediatric Sickle Cell Advancementsstory
The conversation highlights how ex vivo gene therapy is opening up new treatment pathways for young children with sickle cell disease, helping them avoid severe health crises.
Quotes
“I want you to be prepared for the next opportunity that comes down the street for you. I want you to be ready for that.”
Unnamed speaker · 3:03 “The best thing you can do is be collecting those as you go along.”
Unnamed speaker · 4:11 “We are going to be talking with Vox in the Box on twerks news. Vox, how are you?”
Unnamed speaker · 8:51 “We have the FDA actively trying to speed up cell and gene because they have data now from organizations like, you know, you, from you guys, and heavily existing, understanding the platform knowledge and prior scientific information and potentially reducing redundant testing.”
Unnamed speaker · 21:59
Sponsored segments
- Hendron AI 15:47–16:48
About this episode
Cell and gene therapy has entered a new phase. The science is advancing rapidly, but the harder question is increasingly becoming: How do we actually get these therapies to the right patient, at the right treatment center, with the financing, logistics, clinical support, and follow-up required? That is the problem McKesson is trying to address through InspiroGene, its dedicated cell-and-gene commercialization business. McKesson built InspiroGene to connect manufacturers, payers, providers, treatment centers and patients across the CGT journey. McKesson 1. McKesson: Building the infrastructure around the therapy A major area of focus for Joe and McKesson is what happens after a therapy proves clinically viable. In 2026, Joe DePinto and Biologics by McKesson outlined the need for patient hubs purpose-built specifically for cell and gene therapies. These are more complex than conventional specialty-drug hubs because CGT may involve eligibility screening, treatment-center coordination, benefit investigation, financial assistance, scheduling, logistics, long-term follow-up and caregiver support. McKesson Biologics McKesson has also developed an interactive map covering qualified treatment centers across 109 U. S. metropolitan regions, addressing another fundamental problem: patients may need to travel significant distances to receive CGT. McKesson Question for Joe:“Joe, the scientific breakthrough gets most of the headlines, but is the bigger challenge now building the infrastructure that allows a patient to actually receive the therapy?” Follow-up:“Where do you currently see the biggest friction — reimbursement, treatment-center capacity, logistics, patient identification, or ongoing follow-up?” 2. FDA is actively trying to speed cell and gene therapy development FDA has made a noticeable regulatory shift in 2026. In June, FDA issued draft guidance allowing gene-therapy developers to rely more heavily on existing platform knowledge and prior scientific information, potentially reducing redundant testing for products using similar genome-editing technologies. FDA has also issued guidance providing more flexibility around chemistry, manufacturing and controls for CGT products. U. S. Food and Drug Administration FDA says it has now approved close to 50 cell and gene therapies, signaling that CGT is moving well beyond a small experimental category. U. S. Food and Drug Administration TWIRx takeaway:The regulatory conversation is shifting from “Can we safely approve these therapies?” toward “How do we safely accelerate an entire therapeutic platform?”
Transcript
4,892 words · 6 speakers
Topics
- FDA
- Next Dose Summit
- Medica Life
- Inspiro Gene
- Pharmacy 50 Awards
- Pharmacy Podcast Network
- APC
- McKesson
- USC School of Pharmacy
- GAO
Page updated · transcript and summary are machine-generated